+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating ADX-097 in a Phase 2 clinical trial involving male and female participants aged 16 years or older who have Immunoglobulin A Nephropathy IgAN, Lupus Nephritis LN, or Complement Component 3 Glomerulopathy C3G. The study aims to assess the safety, pharmacodynamics, pharmacokinetics, and clinical activity of this investigational drug. Participants will receive weekly subcutaneous injections of ADX-097. The study includes a single treatment group where all participants receive the study drug. Important inclusion criteria include stable background therapy with certain medications like RAAS inhibitors, SGLT2 inhibitors, sparsentan, or atrasentan for at least 8 weeks prior to starting treatment, and kidney biopsy confirmation of their respective diagnoses within specified timeframes depending on the condition. During this study, participants will be monitored for treatment emergent adverse events up to 30 weeks. Researchers will measure changes in urine protein-to-creatinine ratio, estimated glomerular filtration rate, and plasma concentrations of ADX-097 at specified intervals. The total study duration and follow-up assessments extend up to about 26 weeks. The trial is sponsored by Akebia Therapeutics.

Age: 16Years +All GendersPhase 2
4 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the InnAVasc Arteriovenous Graft IG for hemodialysis access in patients with end-stage renal disease ESRD. The study focuses on how well the graft maintains secondary patency at 6 months and monitors any device-related adverse events during this period. The trial is designed for ESRD patients who need hemodialysis and for whom an arteriovenous graft is the next best access option. Participants will receive the InnAVasc AVG surgically implanted in the forearm or upper arm, using standard vascular surgical methods. The graft placement may be in a straight configuration in the upper arm or looped in the forearm or upper arm, avoiding placement across the elbow bend. Patients will continue or start antiplatelet therapy as advised by their physician. The study includes follow-up visits and assessments up to 2 years after implantation to monitor graft use and safety. Participants will be asked to provide informed consent and will undergo periodic evaluations including monitoring of graft patency, successful cannulation within 7 days post-surgery, and sustained use over 24 months. Safety assessments focus on adverse events related to the device. Throughout the trial, participants will attend scheduled visits to support ongoing data collection and safety monitoring over the 2-year period following graft implantation.

Age: 18Years - 90YearsAll GendersPhase Not Applicable
22 locations
R

Actively Recruiting

Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.

Age: 12Years +All GendersPhase 3
316 locations
S

Actively Recruiting

The trial investigates the safety and effectiveness of Voyager Biomedicals Access Device designed to help patients undergoing routine hemodialysis by facilitating the cannulation of arteriovenous fistulas AVFs. This pivotal, interventional, single-arm, open-label study aims to support FDA clearance of the device by assessing its ability to improve access during dialysis and ensure patient safety. The study addresses challenges where AVFs are difficult to cannulate due to depth or accessibility issues and evaluates the device as a potential alternative to other surgical methods. Participants will have the VenaSure device surgically implanted at the dialysis access site, tailored to their clinical needs. Depending on vascular access conditions, one or two devices may be implanted to assist arterial andor venous cannulation. After implantation, patients will be observed for 6 weeks to allow healing. Following this, they will be monitored for 36 months while undergoing routine hemodialysis to assess the devices long-term performance and safety. During the study, participants will have regular follow-up visits to monitor healing, device function, and any adverse effects. Researchers will collect data on the devices ability to facilitate cannulation at 6 months and evaluate safety outcomes at 12 months and beyond. The study lasts approximately 48 to 60 months from enrollment until data collection is complete. Patients exit the study after the final visit with no ongoing device-related safety concerns.

Age: 18Years +All GendersPhase Not Applicable
8 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
E

Actively Recruiting

Researchers are studying adolescents aged 12 to 17 with chronic rhinosinusitis without nasal polyps to evaluate the effectiveness and safety of OPN-375, a nasal spray containing fluticasone propionate. This Phase 3 randomized, double-blind, placebo-controlled study involves about 84 adolescents who will be randomly assigned to receive either OPN-375 or a placebo over 12 weeks. The primary goal is to measure symptom changes from baseline using a composite nasal symptom score after 4 weeks of treatment. Participants will administer 186 micrograms of OPN-375 or a matching placebo intranasally twice daily for 12 weeks. The study includes a pharmacokinetic substudy with up to 14 participants to assess drug absorption. The trial is conducted with multiple visits screening, randomization, and end of study at Week 12, along with telephone check-ins at weeks 4 and 8 to monitor progress. Throughout the study, participants will complete daily symptom diaries and undergo assessments of nasal symptoms, quality of life, and acute exacerbations over 12 weeks. Key measurements include changes in nasal congestion, facial pain, nasal discharge, and patient-reported global impressions of change. Safety and adherence to medication use are monitored, with the total participation lasting about 15 weeks including screening and treatment periods.

Age: 12Years - 17YearsAll GendersPhase 3
24 locations
L

Actively Recruiting

Researchers are collecting long-term safety and performance data on the EndoForce System, a device used to connect a hemodialysis graft to a vein in patients with End Stage Renal Disease ESRD. This observational study focuses on patients who require vascular access for hemodialysis. The device has been approved by the FDA and this study is not testing an experimental therapy or procedure. Participants will have an arteriovenous AV graft implanted using the EndoForce Connector for Endovascular Venous Anastomosis in the upper arm. Since this is an observational study, no new treatments are assigned, and the study monitors the real-world use of the approved device over time. During the 2-year follow-up, researchers will track outcomes such as the incidence of treatment-emergent adverse events, graft patency how long the graft stays open, interventions needed to maintain graft function, and successful device use immediately after the procedure. Participants will follow their usual dialysis schedule and attend follow-up visits to assess safety and device performance throughout the study period.

Age: 18Years +All Genders
2 locations

1-10 of 18

1